Effectiveness of Semiconductor Embedded Therapeutic Socks for Managing Diabetic Neuropathy in Adults Aged 18 to 79

What this Trial Is About

Distal symmetric polyneuropathy, also called diabetic neuropathy, is a common nerve complication of diabetes that affects the longest nerve fibers, especially in the toes and feet. It causes sensory loss, pain, and increases the risk of foot ulcers and amputations, which lowers quality of life. This condition is usually not reversible, and current management focuses on slowing its progression and preventing complications. The study aims to evaluate the use of semiconductor embedded therapeutic socks in managing this condition over a 12-week rehabilitation period. The study compares the effects of semiconductor embedded therapeutic socks, which emit mid and far infrared waves and negative ions to improve blood flow and reduce inflammation, against placebo socks that do not contain this fabric. Participants will wear these socks during the 12-week treatment phase. The socks technology is believed to activate biological pathways that reduce pain and inflammation locally, unlike systemic treatments. The study will collect outcome measures at standard intervals to assess the socks impact on diabetic neuropathy symptoms and function. Participants will be assessed before and after treatment using specific questionnaires and physical exams to measure function, pain, symptom severity, and foot tissue oxygenation. Compliance with sock use will be monitored weekly. The primary outcome is improved patient function measured by standardized scales over 12 weeks. Secondary outcomes include pain reduction, symptom improvement, and better blood oxygen levels in the feet. The study is randomized, double-blind, and will last at least 12 weeks for each participant.

Clinical Outcomes Related to Treatment of Distal Symmetric Polyneuropathy Using Semiconductor Embedded Therapeutic Socks